Menu Search
Equities

Alkermes Plc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
8AK:BRN

Alkermes Plc

Actions
  • Price (CHF)19.75
  • Today's Change0.00 / 0.00%
  • Shares traded1.00k
  • 1 Year change--
  • Beta0.4560
Data delayed at least 15 minutes, as of Oct 30 2019.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Alkermes plc is Ireland-based biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. It focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. It has a manufacturing facility in Wilmington, Ohio.

  • Revenue in USD (TTM)1.52bn
  • Net income in USD338.06m
  • Incorporated2011
  • Employees1.80k
  • Location
    Alkermes PlcConnaught House1 Burlington Road, Dublin 4DUBLIN D04 C5Y6IrelandIRL
  • Phone+353 17728000
  • Websitehttps://www.alkermes.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		ALKS:NSQ since
announced		Transaction
value
Avadel Pharmaceuticals PLCAnnounced22 Oct 202522 Oct 2025Announced11.00%2.18bn
Data delayed at least 15 minutes, as of Feb 06 2026 21:00 GMT.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.